Press releases
24 September, 2026
Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables
• The agreement grants Novo a global exclusive license to Nanexa’s proprietary PharmaShell® atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity,
Read more22 September, 2026
Forge Nano and Nanexa Enter Joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell® Long-Acting Injectable Medicines
Collaboration intended to develop large-scale, GMP-compliant ALD manufacturing equipment supporting Nanexa’s broad portfolio of proprietary and partnered PharmaShell® programs.
Read more27 August, 2026
Nanexa publishes interim report for April – June 2026
Strong commitment and a focus on the commercial side of the business.
Read moreLatest reports
Presentations
25 September 2026
A live commentary with CEO David Westberg and Chairman Göran Ando will take place on September 25 at 11:15 am CET via Infront Direkt Studios
27 August 2026
Q2 report commentary with CEO David Westberg
18–20 May 2026
Nanexa participated in DDF Summit 2026 in Berlin, Germany on 18-20 May
Read the presentation29 April 2026